Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
$0.45
-$0.17(-7.61%)
At close: 4:00 PM EST
$0.45
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.38 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)1.41M
Market Cap
$37.18M
Enterprise Value$233.12B
Total Cash (Recent Filing)$8.68M
Total Debt (Recent Filing)$233.11B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 14, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding83,067,190
10 Day Avg. Volume876,455
30 Day Avg. Volume1,410,275
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)26.09
P/FCF Ratio>-0.01
Enterprise Value/Market Cap6.27K
Enterprise Value/Revenue1.13M
Enterprise Value/Gross Profit-192.68K
Enterprise Value/Ebitda-3.85K
Forecast
1Y Price Target
$3.83Price Target Upside751.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$17.98M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsONS-5010 demonstrated noninferiority to ranibizumab in the NORSE EIGHT trial at week twelve, suggesting comparable efficacy to an established therapy and strengthening regulatory prospects.
European CommercializationCommercial launch of Lytenava in the U.K. and Germany shows increasing uptake and management expectation that European operations may reach breakeven in 2026, supporting a path to scalable revenue.
Valuation UpsideAnalyst maintained a buy rating and raised the price target to ten dollars based on a net present value analysis, indicating analyst-estimated upside from the current share price.
Bears Say
Accounting-related Revenue ImpactReported negative revenue was driven by an increased returns reserve for short-dated products sent to a distributor, an accounting adjustment that depressed reported sales.
Funding And Cash Runway RiskVery limited cash on hand means external financing would be required to fund any additional clinical studies, creating dilution risk and execution uncertainty.
Regulatory Risk In The U.S.FDA issued a complete response letter for the resubmitted biologics application for ONS-5010 citing insufficient evidence of effectiveness, implying an additional well-controlled clinical study may be required for approval.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.38 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $37.18M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is May 14, 2026 which is in 64 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Feb 17, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.227 by $0.007.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 83,067,190 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.227. Following the earnings report the stock price went down -13.878%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.83 (751.11% Upside)
$3.83 (751.11% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.00%
12-Months-Change
Fundamentals
Return on Equity
<0.01%
Trailing 12-Months
Asset Growth
7.25%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$3.83
▲(751.11% Upside)
Technical Analysis
Ownership Overview
19.20% Insiders
2.04% Mutual Funds
0.71% Other Institutional Investors
76.24% Public Companies and Individual Investors